JP2015524845A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524845A5 JP2015524845A5 JP2015527550A JP2015527550A JP2015524845A5 JP 2015524845 A5 JP2015524845 A5 JP 2015524845A5 JP 2015527550 A JP2015527550 A JP 2015527550A JP 2015527550 A JP2015527550 A JP 2015527550A JP 2015524845 A5 JP2015524845 A5 JP 2015524845A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- aag
- arry
- composition
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LLXISKGBWFTGEI-FQEVSTJZSA-N filanesib Chemical compound C1([C@]2(CCCN)SC(=NN2C(=O)N(C)OC)C=2C(=CC=C(F)C=2)F)=CC=CC=C1 LLXISKGBWFTGEI-FQEVSTJZSA-N 0.000 claims description 67
- 229950000133 filanesib Drugs 0.000 claims description 67
- 206010028980 Neoplasm Diseases 0.000 claims description 53
- 201000011510 cancer Diseases 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 41
- 239000012472 biological sample Substances 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 19
- 238000003556 assay Methods 0.000 claims description 14
- 239000000523 sample Substances 0.000 claims description 14
- 230000004044 response Effects 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 230000004797 therapeutic response Effects 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 102000012404 Orosomucoid Human genes 0.000 claims description 4
- 108010061952 Orosomucoid Proteins 0.000 claims description 4
- 238000003018 immunoassay Methods 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 3
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims description 3
- 229960001467 bortezomib Drugs 0.000 claims description 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 3
- 229960002438 carfilzomib Drugs 0.000 claims description 3
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims description 3
- 108010021331 carfilzomib Proteins 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims description 3
- 229960000688 pomalidomide Drugs 0.000 claims description 3
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 description 3
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261682682P | 2012-08-13 | 2012-08-13 | |
| US61/682,682 | 2012-08-13 | ||
| US201261734149P | 2012-12-06 | 2012-12-06 | |
| US61/734,149 | 2012-12-06 | ||
| US201361829779P | 2013-05-31 | 2013-05-31 | |
| US61/829,779 | 2013-05-31 | ||
| PCT/US2013/054807 WO2014028543A1 (en) | 2012-08-13 | 2013-08-13 | Arry-520 for use in treating cancer in a patient with low aag |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015524845A JP2015524845A (ja) | 2015-08-27 |
| JP2015524845A5 true JP2015524845A5 (enExample) | 2016-09-29 |
Family
ID=50101460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015527550A Pending JP2015524845A (ja) | 2012-08-13 | 2013-08-13 | 低ａａｇ患者の癌の治療に使用するためのａｒｒｙ−５２０ |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20150231117A1 (enExample) |
| EP (1) | EP2882436A1 (enExample) |
| JP (1) | JP2015524845A (enExample) |
| KR (1) | KR20150042280A (enExample) |
| CN (1) | CN104869995A (enExample) |
| AU (1) | AU2013302762A1 (enExample) |
| BR (1) | BR112015003192A2 (enExample) |
| CA (1) | CA2881937A1 (enExample) |
| CL (1) | CL2015000348A1 (enExample) |
| CR (1) | CR20150134A (enExample) |
| HK (1) | HK1206275A1 (enExample) |
| IL (1) | IL237227A0 (enExample) |
| IN (1) | IN2015KN00676A (enExample) |
| MX (1) | MX2015002018A (enExample) |
| NZ (1) | NZ631362A (enExample) |
| PH (1) | PH12015500306A1 (enExample) |
| RU (1) | RU2617392C2 (enExample) |
| SG (1) | SG11201501106TA (enExample) |
| WO (1) | WO2014028543A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7449486B2 (en) | 2004-10-19 | 2008-11-11 | Array Biopharma Inc. | Mitotic kinesin inhibitors and methods of use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7618981B2 (en) * | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
| DE602005008953D1 (de) * | 2004-05-21 | 2008-09-25 | Novartis Vaccines & Diagnostic | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin |
| US7449486B2 (en) | 2004-10-19 | 2008-11-11 | Array Biopharma Inc. | Mitotic kinesin inhibitors and methods of use thereof |
| AU2009305588B2 (en) * | 2008-10-16 | 2015-08-13 | Array Biopharma Inc. | Inhibitors of mitosis for increasing apoptosis in therapy |
| US9561214B2 (en) | 2008-10-16 | 2017-02-07 | Array Biopharma Inc. | Method of treatment using inhibitors of mitosis |
-
2013
- 2013-08-13 IN IN676KON2015 patent/IN2015KN00676A/en unknown
- 2013-08-13 AU AU2013302762A patent/AU2013302762A1/en not_active Abandoned
- 2013-08-13 NZ NZ631362A patent/NZ631362A/en not_active IP Right Cessation
- 2013-08-13 KR KR20157006504A patent/KR20150042280A/ko not_active Withdrawn
- 2013-08-13 US US14/421,766 patent/US20150231117A1/en not_active Abandoned
- 2013-08-13 EP EP13750489.0A patent/EP2882436A1/en not_active Withdrawn
- 2013-08-13 JP JP2015527550A patent/JP2015524845A/ja active Pending
- 2013-08-13 CN CN201380052491.8A patent/CN104869995A/zh active Pending
- 2013-08-13 MX MX2015002018A patent/MX2015002018A/es unknown
- 2013-08-13 RU RU2015108740A patent/RU2617392C2/ru active
- 2013-08-13 HK HK15107014.0A patent/HK1206275A1/xx unknown
- 2013-08-13 CA CA2881937A patent/CA2881937A1/en active Pending
- 2013-08-13 SG SG11201501106TA patent/SG11201501106TA/en unknown
- 2013-08-13 BR BR112015003192A patent/BR112015003192A2/pt active Search and Examination
- 2013-08-13 WO PCT/US2013/054807 patent/WO2014028543A1/en not_active Ceased
-
2015
- 2015-02-11 PH PH12015500306A patent/PH12015500306A1/en unknown
- 2015-02-13 CL CL2015000348A patent/CL2015000348A1/es unknown
- 2015-02-15 IL IL237227A patent/IL237227A0/en unknown
- 2015-03-13 CR CR20150134A patent/CR20150134A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chiaravalli et al. | A collateral effect of the COVID‐19 pandemic: delayed diagnosis in pediatric solid tumors | |
| Strand et al. | Long‐term impact of belimumab on health‐related quality of life and fatigue in patients with systemic lupus erythematosus: six years of treatment | |
| Yin et al. | Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis | |
| Li et al. | Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma | |
| Fakhri et al. | Undertreatment of older patients with newly diagnosed multiple myeloma in the era of novel therapies | |
| Muccino et al. | Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough | |
| Fouladi et al. | Five year survival of women with breast cancer in Ardabil, north-west of Iran | |
| Nogueira-Rodrigues et al. | Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer | |
| Maxwell et al. | Population-based study determining predictors of cancer-specific mortality and survival in pediatric high-grade brainstem glioma | |
| Tsai et al. | Induction of osteoclast-like cell formation by leptin-induced soluble intercellular adhesion molecule secreted from cancer cells | |
| Spooner et al. | Stress-induced aberrations in sensory processing predict worse cognitive outcomes in healthy aging adults | |
| Yu et al. | Sequential administration of pemetrexed and cisplatin reprograms tumor immune microenvironment and potentiates PD-1/PD-L1 treatment in a lung cancer model | |
| Whittaker et al. | Cardiac TdP risk stratification modelling of anti-infective compounds including chloroquine and hydroxychloroquine | |
| Albo et al. | Characteristics and potential biomarkers of adult sickle cell patients with chronic pain | |
| Kadooh et al. | Evaluation of the influence of trastuzumab therapy on serum levels of HER-2 protein and breast cancer cell lines | |
| Rosko et al. | Predictive ability of the Cancer and Aging Research Group chemotherapy toxicity calculator in hematologic malignancy | |
| Efficace et al. | Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy | |
| Kiura et al. | Osimertinib in patients with epidermal growth factor receptor T790M advanced non‐small cell lung cancer selected using cytology samples | |
| Mc Hugh et al. | Electroclinical biomarkers of early peripheral neurotoxicity from oxaliplatin | |
| Wang et al. | Upregulation of (CXC motif) ligand 13 (CXCL13) attenuates morphine analgesia in rats with cancer-induced bone pain | |
| Chen et al. | Stable neuronal representations to repeated stimulation underlie cognitive resilience in Alzheimer’s disease pathology | |
| Plazzi et al. | Idiopathic recurrent stupor: Munchausen by proxy and medical litigation | |
| Lemarié et al. | The STEMRI trial: magnetic resonance spectroscopy imaging can define tumor areas enriched in glioblastoma-initiating cells | |
| Spira et al. | A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab | |
| Harbegue et al. | 1738P COVID-19: An additional burden on caregivers of cancer patients in Tunisia |